Current Report Filing (8-k)
February 19 2020 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15 (d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 14, 2020
Immune
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
2431
Aloma Ave #124 Winter Park, FL 32792
|
(Address
of principal executive offices)
|
888-613-8802
(Issuer’s
telephone number)
(Former
name, former address and former fiscal year, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provision (see General Instruction A.2 below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
OTCMKTS
|
|
IMUN
|
Item
5.02.
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers;
|
(d)
On February 14, 2020 the Board of Directors of Immune Therapeutics Inc accepted the resignation of Edward Teraskiewicz. Mr. Teraskiewicz’
s resignation is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s
operations, policies or practices.
On
February 14, 2020 the Board of Directors of Immune Therapeutics Inc accepted the resignation of Jack Brewer. Mr. Brewer’s
resignation is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations,
policies or practices.
February
14, 2020 the Board reconfirmed the appointment of Michael L. Sander as a director to fill a vacancy on the Company’s Board.
Mr. Sander is not appointed to a specific committee. There is no family relationship between Mr. Sander and any of the Company’s
other directors or officers. Mr. Sander accepted such appointments on October 18, 2019.
Michael
Sander BIO
Michael
drives strategy and investment for Sortis Holdings (SOHI), steering the firm’s strategic investment divisions. He sources
compelling opportunities and directs potential moves through a unique lens formed by more than 30 years of technology, finance
and real estate experience. His ability to identify, deconstruct and reconstruct situations into viable concerns has resulted
in added value for developed innovative financial & business operations routines. His career is marked by deep immersion in
the technology industry with investment, M&A activity, capital markets deal structuring which include multiple investment
and ownership positions. He maintains strong working relationships with state and federal agencies keeping abreast of regulatory
developments which enhances the position of his organizations in changing environments. The contribution with acute insight, creativity
and determination in steering a firm’s debt and equity placement, overarching vision, he guides lean teams to successful
execution, with an entrepreneurial bent and broad expertise offering more than 30 years in technology, finance, real estate and
government relations – combine to help create an organizational force that can execute the most complex and challenging
transactions. Has worked in the Sortis Portland, OR headquarters for the past 8 years, managing operations across the United States
as the firm expands abroad. He contributes to Sortis’ deep experience and tireless work ethic, helping the firm close transactions
that total over $10bn and spearheaded the restructuring and subsequent 2013 recapitalization of Oregon-based MBank, delivering
a national turnaround success story at the height of the financial crisis. The bank would eventually reach profitability and be
sold for a 3X return to shareholders. Sortis secures financing, dispositions, and manages assets and portfolios ranging from $1mm
to $1bn . Mr. Sander’s approach to customized solutions that build on a firm’s expertise in a complex capital markets
environment with added exposure on both the national & international stage, coverage experience across primary and secondary
markets, on-the-ground market knowledge, and state-of-the-art technology platforms with a solutions-minded support to management
provide the unique blend relevant to organizations today.Michael drives strategy and investment for Sortis Holdings (SOHI), steering
the firm’s strategic investment divisions. His career is marked by deep immersion in the technology industry with investment,
M&A activity, capital markets deal structuring which include multiple investment and ownership positions.
A
copy of the press release announcing this is being filed with this Form 8-K as Exhibit 99.1.
Item
9.01.
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
Immune
Therapeutics, Inc.
|
Date:
February 19, 2020
|
|
|
/s/ Michael Handley
|
|
Michael Handley
|
|
Chief
Executive Officer and Director,
Immune Therapeutics, Inc.
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024